|
Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer
|
30 June 2023 at 10:15am
|
|
Notification of cessation of securities - OSL
|
29 June 2023 at 6:20pm
|
|
Ethics Committee Approves PANCOSIL Clinical Trial
|
5 June 2023 at 9:55am
|
|
Change of CFO, Company Secretary and Registered Office
|
1 June 2023 at 9:35am
|
|
Resignation of Chief Financial Officer
|
24 May 2023 at 9:35am
|
|
Mr Otto Buttula to Retire from the Board
|
24 May 2023 at 9:25am
|
|
First patient treatment in Italy
|
22 May 2023 at 9:40am
|
|
Becoming a substantial holder
|
12 May 2023 at 9:25am
|
|
Notification of cessation of securities - OSL
|
12 May 2023 at 8:55am
|
|
Change of Director's Interest Notice - Brian Leedman
|
11 May 2023 at 4:50pm
|
|
Change of Director's Interest Notice - Nigel Lange
|
11 May 2023 at 4:50pm
|
|
Top 20 Holdings and Distribution Schedule of OSLO Options
|
11 May 2023 at 11:45am
|
|
Application for quotation of securities - OSL
|
11 May 2023 at 11:00am
|
|
Entitlement Offer Results and Shortfall Notification
|
9 May 2023 at 5:20pm
|
|
First patient enrolled in the TRIPP-FFX Clinical Study
|
3 May 2023 at 9:10am
|
|
OncoSil to streamline operating structure
|
2 May 2023 at 9:10am
|
|
First year anniversary of the OSPREY post-marketing registry
|
1 May 2023 at 9:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 4:30pm
|
|
Late Lodgement of Change in Director's Interest Notice
|
24 April 2023 at 7:35pm
|
|
Update - Proposed issue of securities - OSL
|
24 April 2023 at 12:20pm
|
|
Oral presentation at The Mayo Clinic IMPACT Course
|
24 April 2023 at 9:40am
|
|
Further commercial milestones achieved in Spain
|
24 April 2023 at 9:40am
|
|
Extension of Closing Date of Entitlement Offer
|
21 April 2023 at 4:25pm
|
|
Additional Binding Commitment Received for Entitlement Offer
|
21 April 2023 at 10:30am
|
|
Letter to Ineligible Shareholders
|
28 March 2023 at 5:55pm
|
|
Entitlement Offer - Despatch of Documents
|
28 March 2023 at 5:55pm
|
|
Non-renounceable Rights Issue Offer Prospectus
|
20 March 2023 at 9:05am
|
|
Update - Proposed issue of securities - OSL
|
17 March 2023 at 12:05pm
|
|
Commitment received for Offer and updated Timetable
|
17 March 2023 at 12:05pm
|
|
Proposed issue of securities - OSL
|
17 March 2023 at 10:05am
|
|
Entitlement Offer Presentation
|
17 March 2023 at 10:05am
|
|
Entitlement Offer to raise up to $9.9 million
|
17 March 2023 at 10:05am
|
|
Final Director's Interest Notice
|
6 March 2023 at 6:05pm
|
|
Change of Director's Interest Notice
|
6 March 2023 at 6:00pm
|
|
Cancellation of Unlisted Options and Loan Funded Shares
|
6 March 2023 at 6:00pm
|
|
Half-Yearly Report Results
|
28 February 2023 at 4:45pm
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 4:45pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 12:05pm
|
|
Two key treatment centres treat first patients with OncoSil
|
31 January 2023 at 9:05am
|
|
OncoSil achieves milestone of 10 patients treated in Spain
|
15 December 2022 at 8:40am
|
|
Distribution agreement signed for selected Chinese markets
|
14 December 2022 at 9:25am
|
|
Change of Director's Interest Notice
|
24 November 2022 at 10:05am
|
|
Application for quotation of securities - OSL
|
24 November 2022 at 9:55am
|
|
Cleansing Notice
|
24 November 2022 at 9:50am
|
|
OncoSil to present at TechKnow Invest 2022
|
7 November 2022 at 8:55am
|
|
Change of Director's Interest Notice
|
7 November 2022 at 8:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 5:10pm
|
|
Change of Registry Address
|
31 October 2022 at 4:30pm
|
|
OncoSil to present at AusBioInvest 2022
|
27 October 2022 at 8:40am
|
|
Change of Director's Interest Notice - Nigel Lange
|
25 October 2022 at 6:25pm
|
OncoSil Medical